Home / Pharmaceutical / Neuropathy Partnering 2010-2015

Neuropathy Partnering 2010-2015

Published: Mar 2015 | No Of Pages: 150 | Published By: Current Partnering
The Neuropathy Partnering 2010-2015 report provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in neuropathy partnering deals
  • Top neuropathy deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type
 
The Neuropathy Partnering 2010-2015 provides understanding and access to the neuropathy partnering deals and agreements entered into by the worlds leading healthcare companies.
 
The report provides an analysis of neuropathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors neuropathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
 
This data driven report contains over 30 links to online copies of actual neuropathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of neuropathy partnering trends.
 
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
 
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
 
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
 
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of neuropathy technologies and products.
 
Report scope
 
Neuropathy Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to neuropathy trends and structure of deals entered into by leading companies worldwide.
 
This data driven report includes:
 
  • Trends in neuropathy dealmaking in the biopharma industry since 2010
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 30 neuropathy deals and contract documents where available
  • The leading neuropathy deals by value since 2010
 
In Neuropathy Partnering 2010-2015, the available deals are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in neuropathy partnering
2.1. Introduction
2.2. Neuropathy partnering over the years
2.3. Neuropathy partnering by deal type
2.4. Neuropathy partnering industry sector
2.5. Neuropathy partnering by stage of development
2.6. Neuropathy partnering by technology type
 
Chapter 3 – Average deal terms for neuropathy
3.1 Introduction
3.2 Average deal terms for neuropathy
3.3 Neuropathy headline values with median calculation
3.4 Neuropathy upfront values with median calculation
3.5 Neuropathy milestone values with median calculation
3.6 Neuropathy royalty rates with median calculation
 
Chapter 4 – Active neuropathy dealmakers
4.1. Introduction
4.2 Most active neuropathy dealmakers
4.3. Top neuropathy deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
 
Chapter 5 – Neuropathy dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
 
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products

 

Figure 1: Neuropathy partnering since 2010
Figure 2: Neuropathy dealmaking activity– 2010 to 2015
Figure 3: Neuropathy partnering by deal type since 2010
Figure 4: Neuropathy partnering by industry sector since 2010
Figure 5: Neuropathy partnering by stage of development since 2010
Figure 6: Neuropathy partnering by technology type since 2010
Figure 7: Neuropathy deals with a headline value
Figure 8: Neuropathy deals with upfront payment values
Figure 9: Neuropathy deals with milestone payments
Figure 10: Neuropathy deals with royalty rates, %
Figure 11: Top neuropathy deals by value since 2010
Figure 12: Big pharma – top 50 – neuropathy deals 2010 to 2015
Figure 13: Big pharma neuropathy deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – neuropathy deals 2010 to 2015
Figure 15: Big biotech neuropathy deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +